Previous 10 | Next 10 |
Viatris ( NASDAQ: VTRS ) stock rose ~6% on Oct. 11 amid the company's potential plans to sell its consumer-health assets in Europe which could bring in more than €3B, Bloomberg News reported citing people with knowledge of the matter. Viatris, which was form...
Viatris Inc. ( NASDAQ: VTRS ) shares have weakened from $10.20 to $8.42 since September 12, 2022, and the current price stands at $8.74. The U.S. stock market remains under pressure, and going forward, it will be hypersensitive to any FED comments. The dividend yield is abov...
Summary This was a record-setting September for our family. We received $3,064.59 in September dividend income. Not surprisingly, our portfolio’s market value declined in the third quarter and our portfolio’s average yield increased as a result. ...
Summary The silver lining amid the market collapse is that every new dollar put to work today in dividend stocks comes with an automatic higher yield when compared to just a few weeks ago. First up, I’m thinking about adding to recent spin-off Viatris Inc. Finally, I am...
A lobby group representing the generic drugmakers in Europe has pointed out that the cost inflation, rising energy costs, and price control policies have made manufacturing in the region unsustainable. In an open letter on Tuesday, Medicines for Europe, whose members include leadi...
Dividend stocks can be foundational to your portfolio and help you build it up year after year. The recurring income that these investments generate can help offset declines elsewhere or allow you to collect cash without having to sell shares. Buying stocks trading at discounts can also inc...
Summary We were cautious on Viatris as we felt the three headwinds we anticipated would lead to a guidance cut. We were partially correct on that outcome, but the stock still went lower despite holding the free cash flow outlook. We examine what this injured bird needs to do t...
Mapi Pharma Ltd., a partner of generic drugmaker Viatris Inc. ( NASDAQ: VTRS ), announced Wednesday that its Phase 3 clinical trial for GA Depot, a long-acting version of multiple sclerosis therapy Copaxone, reached the primary endpoint. The trial, designed to evaluate the o...
NESS ZIONA, Israel, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development pharmaceutical company focused on introducing innovative long-acting depot injectable products, announced today positive top-line results from the GA Depot (a long ac...
Summary There is one notable trade that is not a buy this month as I decided to shuttle Warner Bros. Discovery, Inc. Today, it seems that every company is engaged in accounting trickery fooling shareholders with crap spin-offs that only disguise real dividend cuts. I continue ...
News, Short Squeeze, Breakout and More Instantly...
NORTHAMPTON, MA / ACCESSWIRE / July 23, 2024 / No country can make every medicine people need, and no medicine is made in every country. If a country or region relies on supply only from within their region and they experience a crisis, there is a risk people won't get the medicines they need, w...
NORTHAMPTON, MA / ACCESSWIRE / July 18, 2024 / Viatris is a global healthcare company focused on bringing high-quality medicines to patients through a hybrid approach that bridges the traditional divide between generics and brands, combining the best of both, to more holistically address healthc...
2024-07-15 10:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...